Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE Marks T-SPOT®.COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection

Rhea-AI Summary

On March 4, 2021, Oxford Immunotec Global PLC (Nasdaq: OXFD) announced the launch of its T-SPOT.COVID test, designed to qualitatively assess T cell immune responses to SARS-CoV-2. The test has received a CE mark and an EUA request has been filed with the FDA. Clinical studies show a high positive agreement of 96.6% with PCR results within 60 days of infection. The test complements antibody serology, enhancing the understanding of an individual's immune response. Furthermore, Oxford Immunotec is in the process of being acquired by PerkinElmer.

Positive

• T-SPOT.COVID test shows 96.6% positive agreement with PCR tests within 60 days.
• CE mark obtained; EUA request submitted to the FDA, indicating regulatory progress.
• T-SPOT.COVID complements antibody tests, providing a fuller picture of immune responses.

Negative

• None.

OXFORD, United Kingdom and MARLBOROUGH, Mass., March 4, 2021 /PRNewswire/ -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the "Company"), a global, high-growth diagnostics company, announced that today it has released the T-SPOT.COVID test, a CE marked ELISPOT based test intended for qualitative detection of a cell mediated (T cell) immune response to SARS-CoV-2 in human whole blood. The company has filed an EUA request to the FDA for the test.

Serology does not give the full picture of the adaptive immune response to SARS-CoV-2 infection. Antibodies are not always produced in response to SARS-CoV-2 infection, or may be delayed^1,2. Antibodies can also wane quickly after infection⁴ and reports show T cells may be more long lived than the antibody response³. In the absence of an antibody response, the T cell response may be protective from SARS-CoV-2 infection⁵.

In a clinical study using samples collected in the US, the T-SPOT.COVID test was proven to detect a SARS-CoV-2 cell mediated (T cell) immune response in PCR positive individuals, even with negative serology test results⁶. The T-SPOT.COVID test therefore complements results obtained by antibody serology to give a more comprehensive view of an individual's adaptive immune response to SARS-CoV-2 infection. The test could also be used, for example, alongside serology tests to support clinical assessment of individuals who present with suspected COVID-19 but are PCR negative.

In the study, the T-SPOT.COVID test had a positive agreement with PCR-results of 96.6% (84/87) in SARS-CoV-2 infected individuals <60 days after first PCR positive result. At >60 days (with the furthest time point after first positive PCR test result being >240 days) positive agreement remained high at 83.3% (40/48). The T-SPOT.COVID test detected substantially more people with previous positive PCR results than serology in the cohort, whose positivity rate was lower and declined faster over time.

In an endemic cohort of US individuals selected to be at a relative lower risk of SARS-CoV-2 infection (based on the absence of self-reported symptoms, negative serology results and no prior history of a positive PCR test result for SARS-CoV-2) the T-SPOT.COVID  test had a negative agreement of 98.0% (96/98)⁶. We cannot exclude the possibility that a proportion of this group had, or still have, an asymptomatic infection, seronegative at the time of testing, but in whom the T-SPOT.COVID test was able to detect a T cell response.

Phill Keefe, Senior VP, Product Design, Development and Delivery at Oxford Immunotec said, "T cells and antibodies are two arms of the adaptive immune response. The detection and measurement of each can provide different insights about disease activity and an individual's personal immunity."

The Company developed the T-SPOT.COVID test as an evolution of its T-SPOT^® Discovery SARS-CoV-2 assay, a research use only test used to gain insights about the immune response to SARS-CoV-2.

Dr. Peter Wrighton-Smith, CEO of Oxford Immunotec, said, "The T-SPOT^® Technology platform is a standardised way of measuring T cells. It has been proven in clinical use for over 18 years with another major infectious disease, tuberculosis, which kills around 1.5 million people every year. Our T-SPOT.COVID test is tailored specifically for the detection and measurement of an individual's T cell response to SARS-CoV-2 infection. Having the ability to determine an individual's immune response to SARS-CoV-2 has the potential to support a wide range of needs in our battle against the COVID-19 pandemic."

For further information visit www.tspotcovid.com.

Oxford Immunotec has entered in an agreement to be acquired by PerkinElmer (NYSE: PKI). The transaction is expected to close shortly.

1. Tan W, Lu Y, Zhang J et al. Viral kinetics and antibody responses in patients with COVID-19. medRxiv. 2020 March 26. Preprint. https://doi.org/10.1101/2020.03.24.20042382
2. Altmann DM, Boyton RJ. SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection. Sci Immunol. 2020;5:eabd6160
3. Zuo J, Dowell A, Pearce H et al. Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection. bioRxiv. 2020. doi: 10.1101/2020.11.01.362319
4. Ibarrondo FJ, Fulcher JA, Goodman-Meza D et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med. 2020; 383: 1085-1087
5. Wyllie D, Mulchandani R, Jones HE et al. SARS-CoV-2 Reactive T cell numbers are associated with protection from COVID-19: A prospective cohort study. medRxiv. doi: 10.11012020.11.02.20222778
6. Package Insert PI-T-SPOT.COVID-IVD-US v3 T-SPOT-COVID-US-PI-v3-1.pdf

T-SPOT, T-Cell Xtend, T-SPOT Discovery SARS-CoV-2 and the Oxford Immunotec logo, are trademarks of Oxford Immunotec Limited.

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company. We bring energy and invention to a world in need of diagnostic truth. We are uniquely placed as the only company in the world offering regulated ELISPOT assays for T cell measurement, with approval around the globe. Our leading product, the T-SPOT^®.TB test, is used for diagnosing infection with Tuberculosis, the world's largest cause of death from infectious disease. The Company has over 18 years' experience as a manufacturer of IVD tests, operating under a fully audited Quality Management System, ensuring rigorous batch control. The company has manufactured in excess of 20 million clinical T cell tests for TB infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States (where it has received pre-market approval from the Food and Drug Administration), Europe (where it has obtained a CE mark), as well as Japan and China. The Company is headquartered near Oxford, U.K. and in Marlborough, MA. Additional information can be found at www.oxfordimmunotec.com.

About T-SPOT.COVID

Oxford Immunotec has been developing and strengthening its expertise in T cell measurement for over 18 years since the introduction of its T-SPOT technology in the field of TB diagnostics. In that time, we have taken the classic ELISPOT technique and developed it into the world leading proprietary T-SPOT technology platform we now use to measure T cell immune responses, improving performance, standardizing results, and streamlining the workflow. The ELISPOT technique is exceptionally sensitive since the target cytokine is captured directly around the secreting cell making ELISPOT assays much more sensitive than conventional ELISA assays. The test enumerates effector T cells responding to stimulation using two separate peptide pools measured in parallel in individual wells. T-SPOT.COVID antigen panels are designed as overlapping peptides spanning sequences of the Spike and Nucleocapsid proteins. This design offers maximum epitope coverage for enhanced detection of T cell reactivity and no HLA restrictions. Antigenic formulations of 253 peptides covering the most immunogenic regions of the virus genome allows measurement of the breadth of immunity and ensures the impact of point mutations is minimized. Specificity to SARS-CoV-2 has been enhanced by removing potentially cross-reactive peptide sequences with high homology to other coronaviruses.

Forward-Looking Statements

This release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this release are forward-looking statements. This includes statements about Oxford Immunotec's anticipated plans and objectives, future performance and revenues, financial condition, prospects for sales of its products, growth, strategies, expectations and objectives of management. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements contained in this release reflect Oxford Immunotec's current expectations and are subject to risks and uncertainties. Actual results may differ materially from those projected or implied by forward-looking statements. Other factors that could adversely affect Oxford Immunotec's business and prospects are described under the "Risk Factors" section in its filings with the Securities and Exchange Commission ("SEC"). Oxford Immunotec's SEC filings are available for free by visiting the investor section of its website, www.oxfordimmunotec.com, or the SEC's website, www.sec.gov.

Investors should give careful consideration to these risks and uncertainties. Forward-looking statements contained herein are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. Investors should not place undue reliance on forward-looking statements contained herein, which speak only as of the date of this release. Oxford Immunotec does not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.

For Investor Inquiries:
Matt McLaughlin
Chief Financial Officer
Oxford Immunotec
Tel: +1 (508) 573-9953
mtmclaughlin@oxfordimmunotec.com 

For Media Enquiries:
US: Mary Conway
MKC Strategies, LLC
Tel: +1 (516) 606-6545 
MConway@MKCStrategies.com

UK: Megan Anderson
ZPB ASSOCIATES
mobile: 07597572287
office: (020) 7018 1124
megan.anderson@zpb-associates.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/oxford-immunotec-submits-emergency-use-authorization-request-to-the-fda-and-ce-marks-t-spotcovid-a-test-for-the-detection-of-a-cell-mediated-t-cell-immune-response-to-sars-cov-2-infection-301240966.html

SOURCE Oxford Immunotec

FAQ

What is the T-SPOT.COVID test from OXFD?

The T-SPOT.COVID test is designed to detect T cell immune responses to SARS-CoV-2, providing insights into an individual's immunity.

When did OXFD announce the T-SPOT.COVID test?

The announcement was made on March 4, 2021.

What regulatory approvals has the T-SPOT.COVID test received?

The T-SPOT.COVID test has received a CE mark and an Emergency Use Authorization request has been filed with the FDA.

What is the significance of the T-SPOT.COVID test's positive agreement rate?

The test demonstrated a 96.6% positive agreement rate with PCR results, confirming its effectiveness in detecting immune responses.

Is Oxford Immunotec being acquired?

Yes, Oxford Immunotec has agreed to be acquired by PerkinElmer, with the transaction expected to close shortly.